This product comprises a polyclonal population of HEK293T cells with CRISPR/Cas9-mediated disruption of the GTF2I gene. The polyclonal format provides a heterogeneous pool of edited alleles, enabling robust loss-of-function studies without clonal bias. These cells serve as a versatile model for investigating GTF2I-dependent transcriptional regulation and signaling pathways.
The HEK293T host cell line is derived from human embryonic kidney epithelial cells and stably expresses the SV40 large T-antigen, which supports episomal replication of plasmids containing the SV40 origin of replication. This feature, combined with high transfection efficiency, makes HEK293T cells a widely used system for protein expression, viral production, and functional genomic screens.
GTF2I encodes a multifunctional transcription factor that integrates signals from multiple upstream pathways. Activated by kinases such as Bruton??s tyrosine kinase (BTK), Src family kinases, and MAPKs (ERK, JNK), GTF2I translocates to the nucleus, where it interacts with cofactors including USF1, SRF, E2F1, and EP300. It regulates key downstream targets like c-FOS, c-MYC, CCND1, TGFBR1, and VEGFA, thereby modulating pathways involved in cell proliferation, differentiation, and immune responses.
In HEK293T cells, GTF2I knockout disrupts the integration of signals from pathways such as MAPK/ERK, TGF-??, and NF-??B, providing a clean genetic background to dissect the transcription factor??s role in processes like cell cycle control and signal transduction. Given the cell line??s epithelial origin and SV40 T-antigen-mediated immortalization, this model is particularly suited for studying oncogenic mechanisms and evaluating drug targets in cancer-related contexts.
Typical applications include functional genomics using RNA-seq or ChIP-qPCR to define GTF2I target genes, signaling pathway analysis via western blotting and dual-luciferase reporter assays, and cell proliferation assays to assess tumorigenic potential. The knockout cells also facilitate drug target validation studies in breast cancer, gastric cancer, and thymic epithelial tumors. For further information or to discuss specific experimental needs, please contact Ascent Research.
